Disc Medicine (IRON) Research & Development (2020 - 2026)
Disc Medicine (IRON) posted quarterly Research & Development of $46.9 million for Q2 2026, up 1.33% year-over-year from $46.3 million in Q2 2025, and up 2.24% quarter-over-quarter from $45.9 million in Q1 2026.
Disc Medicine (IRON) Research & Development (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Research & Development for 7 consecutive years, with $46.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Research & Development rose 1.33% year-over-year to $46.9 million; the TTM figure through Jun 2026 stood at $189.4 million (up 53.28% YoY), while the FY2025 annual figure was $170.6 million, up 76.52% from the prior year.
- Research & Development advanced to $46.9 million in Q2 2026 per IRON's latest filing, from $45.9 million in the prior quarter.
- Across five years, Research & Development topped out at $50.3 million in Q3 2025 and bottomed at $7.7 million in Q2 2022.
- Historically, Research & Development has averaged $25.7 million across 5 years, with a median of $23.6 million in 2024.
- On a YoY basis, Research & Development climbed as much as 191.78% in 2022 and fell as far as 41.39% in 2022.
- Disc Medicine's Research & Development stood at $10.0 million in 2022, then soared by 125.29% to $22.6 million in 2023, then climbed by 9.89% to $24.8 million in 2024, then surged by 86.41% to $46.2 million in 2025, then climbed by 1.53% to $46.9 million in 2026.
- Business Quant data shows IRON's Research & Development at $46.9 million in Q2 2026, $45.9 million in Q1 2026, and $46.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - | 46.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 46.93 Mn |
| Mar 31, 2026 | 45.90 Mn |
| Dec 31, 2025 | 46.22 Mn |
| Sep 30, 2025 | 50.33 Mn |
| Jun 30, 2025 | 46.32 Mn |
| Mar 31, 2025 | 27.76 Mn |
| Dec 31, 2024 | 24.80 Mn |
| Sep 30, 2024 | 24.69 Mn |
| Jun 30, 2024 | 23.49 Mn |
| Mar 31, 2024 | 23.70 Mn |
| Dec 31, 2023 | 22.57 Mn |
| Sep 30, 2023 | 14.42 Mn |
| Jun 30, 2023 | 12.10 Mn |
| Mar 31, 2023 | 20.18 Mn |
| Dec 31, 2022 | 10.02 Mn |
| Sep 30, 2022 | 7.89 Mn |
| Jun 30, 2022 | 7.71 Mn |
| Mar 31, 2022 | 7.82 Mn |
| Dec 31, 2021 | -10.91 Mn |
| Sep 30, 2021 | 13.46 Mn |